Homemade pyri solution- problems Treatment 3/6/2024
A user mixed a pyrilutamide solution and noticed undissolved powder at the bottom, questioning if this is normal and how long to wait before applying it. They wished others good luck with their treatments.
View this post in the Community →
Similar Community Posts Join
6 / 6 resultscommunity What I’ve learned From 8 Months on Pyrilutamide
Pyrilutamide helps maintain hair density but is less effective than finasteride and needs consistent use. It works best with minoxidil, alfatrodial, and nizoral, though it is costly and inconvenient.
community Anyone having success with pyrilutamide?
Pyrilutamide is being discussed for hair loss treatment, with one user reporting no success after six months and another using it alongside finasteride for two months. The conversation seeks recommendations and experiences with pyrilutamide.
community So why did the first pyrilutamide phase III fail?
Pyrilutamide's inconsistent trial results, with phase II showing positive hair growth and phase III failing to show significant gains, possibly due to COVID-related disruptions. Users discuss modest results from kx-826 treatment.
community My thoughts on Pyrilutamide after 6 months
Pyrilutamide is effective for mild hair loss, especially when finasteride isn't an option, but it's less effective than finasteride and requires consistent application. It's best for early-stage hair loss and works well in combination with other treatments like minoxidil.
community Pyrilutamide and Topical Fin/Min
Pyrilutamide should be applied before topical minoxidil and finasteride, allowing time between applications to prevent degradation from water. Users discuss the order and timing of applying these treatments for hair loss.
community Pyrilutamide for Hair Loss!? (Ft. Steve Cook)
Pyrilutamide is discussed as a potential hair loss treatment, acting as an androgen receptor antagonist. The conversation questions if it can maintain hair long-term without using finasteride.
Related Research
6 / 6 resultsresearch 587 Efficacy and Safety of topical KX-826 in Male Subjects with Androgenetic Alopecia:A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study
Among men with androgenetic alopecia, this study found that taking 5 mg of KX-826 twice daily significantly increased hair count compared to a placebo, with the treatment being well-tolerated and no serious adverse effects reported.
research Development and Validation of Androgen-induced Hair Loss and Anagen Induction Mouse Models for Pharmacological Evaluation of Anti-Androgenic Agents
This study evaluated androgen-induced hair loss and anagen induction mouse models, finding that Minoxidil and Pyrilutamide significantly promoted hair growth by decreasing androgen receptor protein levels and enhancing the Wnt/β-Catenin signaling pathway, supporting their use in studying novel treatments for androgenetic alopecia.
research The state‐of‐the‐art in the management of androgenetic alopecia: A review of new therapies and treatment algorithms
This abstract outlines a guide reviewing both FDA-approved and off-label therapies for androgenetic alopecia and proposes treatment algorithms based on scientific research, highlighting a gap in common treatments for this prevalent condition.
research Novel DualSoftDrug Strategy Enables Developmentof Topical Androgen Receptor Antagonists with Enhanced Efficacy andOptimized Safety for Androgenetic Alopecia
In this study, the researchers reported that the optimized compound 39 demonstrated potent AR antagonism and favorable pharmacokinetics in a hair-growth mouse model, achieving similar efficacy to pyrilutamide with faster onset and preserved safety, offering promise for next-generation topical AR antagonist development.
research Novel DualSoftDrug Strategy Enables Developmentof Topical Androgen Receptor Antagonists with Enhanced Efficacy andOptimized Safety for Androgenetic Alopecia
This study found that the optimized topical AR antagonist 39, derived from 14-P1, demonstrated potent AR antagonism and comparable efficacy to pyrilutamide in a hair-growth mouse model, with a faster onset and favorable safety profile.
research Novel DualSoftDrug Strategy Enables Developmentof Topical Androgen Receptor Antagonists with Enhanced Efficacy andOptimized Safety for Androgenetic Alopecia
In this study, researchers optimized the soft drug AR antagonist 14-P1 to create candidate 39, which demonstrated effective AR antagonism and safety in a hair-growth mouse model, showing similar efficacy to pyrilutamide but with quicker onset and a lower risk of systemic toxicity.